Bell Potter has good things to say about this stock. The post Why this ASX 200 stock could jump 25% appeared first on The ...

Q2 2025 Management View Catherine E. Owen Adams, CEO, stated that "Our second quarter performance reinforces the momentum we're building across all facets of our business from commercial strength to ...

ACADIA’s $1B+ 2025 revenue outlook is driven by NUPLAZID and DAYBUE, with ACP-101 offering optional upside despite risks. Read why ACAD stock is a buy.

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the second quarter ended June 30, 2025.

In long-term studies, 2.2% of patients discontinued treatment with DAYBUE due to weight loss. Monitor weight and interrupt, reduce dose, or discontinue DAYBUE if significant weight loss occurs.

Daybue recorded net product sales of $91.2 million in the reported quarter, up 36% year over year and 8% sequentially, driven by the growth in the drug’s unit sales.

Acadia Pharmaceuticals Inc. today announced that the journal Med published results from the open-label study, DAFFODIL™, evaluating the safety, tolerability and exploratory efficacy of DAYBUE ...

Acadia looks for third-quarter sales of Daybue in the range of $45 million to $55 million. It projects full-year sales of Nuplazid will be between $530 million and $545 million.

Acadia expects to make Daybue available in the United States by the end of April 2023. Additionally, per the terms of the company’s 2018 exclusive license agreement with Neuren Pharmaceuticals ...

7 DAYBUE Canadian Product Monograph, [October] 2024 8 May DM, Neul JL, Satija A, et al. Real-world clinical management of individuals with Rett syndrome: a physician survey.

Daybue is supplied as a strawberry-flavored oral solution containing 200mg of trofinetide per mL. The dosage is determined by patient weight and can be administered orally or via gastrostomy tube.